Arthneeti
Latest: Anthem Bioscienc Q1 FY27 results →All Q1 FY26 results →
AB

Anthem Bioscienc

Q1 FY26Pharmaceuticals & Biotechnology

Anthem Bioscienc Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Price₹871
Market cap₹50.1K Cr
P/E84.5
Updated23 Aug 2026
Read4 min read

The short version

Anthem Biosciences expects steady growth with a historical CAGR of around 20% year-on-year, maintaining this outlook for FY25 vs FY26 and beyond. Anthem Biosciences targets steady margins in EBITDA, gross margin, and PAT margin levels, maintaining around 38% EBITDA margin as seen in FY25.

From Anthem Bioscienc's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Anthem Biosciences expects steady growth with a historical CAGR of around 20% year-on-year, maintaining this outlook for FY25 vs FY26 and beyond.
  • Growth is driven largely by commercialized molecules, with multiple products seeing increased demand across several clients.
  • There is significant headroom for growth across existing commercial products, but sales volumes may not increase every quarter due to customer stocking patterns.
  • The company plans capacity expansions ahead of demand to support future growth, anticipating customers’ needs and new modalities.
  • Development-stage products and new modalities like peptides and ADCs will contribute to growth over multiple years, though with longer gestation and smaller volumes initially.

2 more points from Anthem Bioscienc's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Anthem Bioscienc said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Anthem Biosciences is undertaking capacity expansion with a capital commitment of about INR 150 crores to complete Unit 2 and Unit 3 commissioning.
  • Unit 4 expansion is in early planning stage; detailed plans and capex numbers will be shared once finalized.
  • Expansion funding will primarily come from internal accruals and existing net cash balance of about INR 785 crores.
  • The company has recently commissioned 54 kiloliters of custom synthesis capacity in Q1 FY26; balance 76 kiloliters to be added by end of calendar year.
  • Additional 25 kiloliters peptide synthesis capacity built in NeoAnthem unit as part of custom synthesis expansion.

2 more points from Anthem Bioscienc's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Anthem Bioscienc said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Anthem Biosciences has multiple ongoing projects with clients, both in development and commercialization stages, indicating a robust order book.
  • The company works with global pharmaceutical companies and handles several late-stage Phase 3 molecules, some moving to commercialization.
  • They have around 10 molecules in Phase 3 as of March 2025, with 2 recently approved and commercialized, indicating active project pipeline.
  • Anthem is also involved in lateral projects and becoming a second source for existing products, adding to their pending order prospects.
  • Capacity expansions (units 2, 3, and upcoming unit 4) are aligned with the expected growth in order volumes.

2 more points from Anthem Bioscienc's call on order book

Create a free account to keep reading this call

Anthem Bioscienc — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹611 Cr, net profit ₹190 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Anthem Biosciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • RPG LifeScience. (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharma. (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories Ltd (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem Ltd (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Anthem Bioscienc and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Anthem Bioscienc Q1 FY26 results?

Anthem Biosciences expects steady growth with a historical CAGR of around 20% year-on-year, maintaining this outlook for FY25 vs FY26 and beyond. Anthem Biosciences targets steady margins in EBITDA, gross margin, and PAT margin levels, maintaining around 38% EBITDA margin as seen in FY25.

What is Anthem Bioscienc share price analysis?

Anthem Bioscienc currently shows a neutral. The stock trades at a P/E of 84.5 with a market cap of ₹50,132 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anthem Bioscienc planning capital expenditure?

Anthem Biosciences is undertaking capacity expansion with a capital commitment of about INR 150 crores to complete Unit 2 and Unit 3 commissioning.

Keep Anthem Bioscienc on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.